Oragenics, Inc. (NYSE MKT: OGEN) today announced its intention to offer
and sell shares of its common stock in an underwritten public offering
pursuant to its existing shelf registration statement. All of the shares
in the proposed offering are to be sold by Oragenics.
Griffin Securities, Inc. is acting as sole underwriter for the proposed
offering on a firm commitment basis. The offering is subject to market
and other conditions, and there can be no assurance as to whether or
when the offering may be completed, or as to the actual size or terms of
the offering.
Oragenics intends to use the net proceeds from the public offering for
continued development of its lantibiotics program and for general
corporate and working capital purposes.
The securities described above are being offered pursuant to a shelf
registration statement (File No. 333-190609), which was declared
effective by the United States Securities and Exchange Commission
(“SEC”) on August 26, 2013. A preliminary prospectus supplement relating
to the offering has been filed with the SEC. Copies of the preliminary
prospectus supplement and the accompanying prospectus relating to this
offering may be obtained at the SEC's website at www.sec.gov,
or by request at Griffin Securities, Inc. 17 State Street New York, NY
10004.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there be any
sale of these securities in any state or other jurisdiction in which
such offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or other jurisdiction.
About Oragenics, Inc.
Oragenics, Inc. is focused on becoming the world leader in novel
antibiotics against infectious disease and probiotics for oral health
for humans and pets. Oragenics has established exclusive worldwide
channel collaborations for lantibiotics and probiotics, with Intrexon
Corporation Inc., a synthetic biology company. The lantibiotics
collaboration will allow Oragenics access to Intrexon’s proprietary
technologies with the idea of accelerating the development of much
needed new antibiotics that will work against resistant strains of
bacteria. The probiotics collaboration will allow Oragenics access to
Intrexon’s proprietary technologies to develop and commercialize
probiotics, specifically the direct administration to humans of
genetically modified probiotics for the treatment of diseases of the
oral cavity, throat, sinus and esophagus, including, but not limited to,
aphthous stomatitis and Behcet’s disease. Oragenics also develops,
markets and sells proprietary probiotics specifically designed to
enhance oral health for humans and pets, under the brand names Evora
and ProBiora in over 13 countries worldwide.
Safe Harbor Statement: Under the Private Securities Litigation
Reform Act of 1995: This release includes forward-looking statements
that reflect the Company’s current views with respect to future events
and financial performance. These forward-looking statements are based on
management’s beliefs and assumptions and information currently
available. The words “believe,” “expect,” “anticipate,” “intend,”
“estimate,” “project” and similar expressions that do not relate solely
to historical matters identify forward-looking statements. Investors
should be cautious in relying on forward-looking statements because they
are subject to a variety of risks, uncertainties, and other factors that
could cause actual results to differ materially from those expressed in
any such forward-looking statements. These factors include, but are not
limited to our ability to raise additional capital to sustain our
operations and those set forth in our most recently filed annual report
on Form 10-K and quarterly report on Form 10-Q, and other factors
detailed from time to time in filings with the U.S. Securities and
Exchange Commission. We expressly disclaim any responsibility to update
forward-looking statements.
For more information about Oragenics, visit www.oragenics.com.
Follow Oragenics on Facebook
and Twitter.
Copyright Business Wire 2013